We are evolving targeted protein degradation to transform the landscape of drug discovery by utilizing the cell’s normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering impactful medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. Through our novel "function-first" approach, our goal is to expand the scope of degradable targets that cause human disease.
Our lead oncology monotherapy compound, FFT-012, degrades an undruggable transcription factor at the end of the Wnt pathway which provides multiple applications in solid tumors. In addition to the Wnt and additional portfolio programs, we are engaging our oncology assets towards combinations with antibodies to provide novel Degrader Antibody Conjugates (DACs). By replacing the cytotoxic payloads of an Antibody Drug Conjugate (ADC), f5 Therapeutics is attempting to widen the therapeutic index of this modality.
Company Details
- Employees
- 4
- Founded
- -
- Address
- San Diego, California 92127, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- f5therapeutics.com
- HQ
- San Diego, California
F5 Therapeutics Incorporated Questions
F5 Therapeutics Incorporated's website is f5therapeutics.com
F5 Therapeutics Incorporated's LinkedIn profile is https://www.linkedin.com/company/f5-therapeutics-incorporated
F5 Therapeutics Incorporated has
4 employees.
View email and phone details for 4
employees at F5 Therapeutics Incorporated.
F5 Therapeutics Incorporated's industry is
Biotechnology Research
F5 Therapeutics Incorporated's top competitors are
Neurano Bioscience,
Origami Therapeutics, Inc.,
Aluda Pharmaceuticals, Inc.,
Aivocode,
Palm Therapeutics,
Myogene Bio,
Endure Biotherapeutics,
Trestle Biotherapeutics,
Tumorgen, Inc.,
Styx Biotechnologies.
F5 Therapeutics Incorporated's categories are Biotechnology Research
F5 Therapeutics Incorporated's founding year is 2020
